Literature DB >> 30202955

Immediate and substantial evolution of T-cell repertoire in peripheral blood and tumor microenvironment of patients with esophageal squamous cell carcinoma treated with preoperative chemotherapy.

Chaoting Zhang1, Heyilimu Palashati1, Qin Tan2, Wenjing Ku1, Yu Miao3, Hongchao Xiong4, Zheming Lu1.   

Abstract

Preoperative chemotherapy could decrease tumor size and improve overall survival for esophageal squamous cell carcinoma (ESCC), and moreover, rational combination of chemotherapy and immunotherapy could increase likelihood of inducing an effective antitumor immune response. However, the immunologic impact of chemotherapeutic drugs originally chosen for cancer treatment due to the direct toxicity is poorly understood. We assess the effect of a combination of clinically approved chemotherapeutic drugs [paclitaxel-nedaplatin (PTX-NDP)] on T-cell receptor (TCR) repertoires of peripheral T cells and tumor-infiltrating lymphocytes (TILs) from five patients with primary ESCC. We found that PTX-NDP therapy induced immediate and substantial changes in clonotype frequencies of peripheral T cells and TILs, and moreover, compared with clonal amplification, clonal contraction was more likely to occur in more abundant clones in patients with ESCC. Significant increases in TCR diversity were observed in peripheral T cells but not in TILs after PTX-NDP therapy. Reconstruction of posttreatment TILs was not merely a result of local expansion or contraction of pretreatment TILs, but also-at least in part-a consequence of the migration of peripheral T cells into the chronically inflamed tumor microenvironment. Our findings uncover further insight into T-cell immune response modulated with chemotherapy, providing for theoretical bases for rational combination strategy of chemotherapy and immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30202955     DOI: 10.1093/carcin/bgy116

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  6 in total

1.  Harnessing radiation to improve immunotherapy: better with particles?

Authors:  Marco Durante; Silvia Formenti
Journal:  Br J Radiol       Date:  2019-07-22       Impact factor: 3.039

Review 2.  Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook.

Authors:  Zixian Jin; Jianfei Shen; Chunguo Wang; Dong Chen; Bo Zhang; Jian Zhang; Jaffer A Ajani; Jaafar Bennouna; Joseph Chao; Harry H Yoon; Hongyu Zhu; Yuhang Ruan; Chengchu Zhu; Anyi Xu
Journal:  Ann Transl Med       Date:  2021-07

3.  Prognostic value of the baseline circulating T cell receptor β chain diversity in advanced lung cancer.

Authors:  Jiaqi Wang; Zhixin Bie; Yajing Zhang; Lin Li; Yujie Zhu; Yi Zhang; Xin Nie; Ping Zhang; Gang Cheng; Xuebing Di; Xiaoguang Li; Shujun Cheng; Lin Feng
Journal:  Oncoimmunology       Date:  2021-03-17       Impact factor: 8.110

Review 4.  Advances in Drug Resistance of Esophageal Cancer: From the Perspective of Tumor Microenvironment.

Authors:  Siyuan Luan; Xiaoxi Zeng; Chao Zhang; Jiajun Qiu; Yushang Yang; Chengyi Mao; Xin Xiao; Jianfeng Zhou; Yonggang Zhang; Yong Yuan
Journal:  Front Cell Dev Biol       Date:  2021-03-19

5.  Clonal Expansion of Tumor-Infiltrating T Cells and Analysis of the Tumor Microenvironment within Esophageal Squamous Cell Carcinoma Relapsed after Definitive Chemoradiation Therapy.

Authors:  Takahiro Mori; Kenichi Kumagai; Keisuke Nasu; Takamasa Yoshizawa; Koji Kuwano; Yoshiki Hamada; Hideki Kanazawa; Ryuji Suzuki
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

6.  Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade.

Authors:  Cihui Yan; Xiaoxue Ma; Zhoubo Guo; Xiaoying Wei; Dong Han; Tian Zhang; Xi Chen; Fuliang Cao; Jie Dong; Gang Zhao; Xuan Gao; Tao Wang; Yao Jiang; Ping Wang; Qingsong Pang; Wencheng Zhang
Journal:  Oncoimmunology       Date:  2022-01-13       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.